Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. Show More...